<?xml version="1.0" encoding="UTF-8"?>
<p>We provide the first document on the global impact of SARS-CoV-2 infection on paediatric IBD to date, from which we have generated guidance points for paediatric gastroenterologists in the era of this COVID-19 pandemic. The general message of continuing current IBD treatments is supported by the Chinese and South Korean experience reported here of âˆ¼20% disease exacerbation in children whose infliximab infusions were delayed.</p>
